To further validate the hypothesis of a possible therapeutic approach, based on targeting P53 and BMI-1, for counteracting cancer growth and MDR, the effects of PRIMA-1MET and PTC596 on EMT were evaluated. This evidence concerns the gene TP53 and cancer.